Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tarsus Pharmaceuticals, Inc. (TARS : NSDQ)

• Company Description    Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif. Number of Employees: 46

• Price / Volume Information    Yesterday's Closing Price: $13.70 Daily Weekly Monthly 20 Day Moving Average: 377,147 shares Shares Outstanding: 20.73 (millions) Market Capitalization: $283.96 (millions) Beta: 1.44 52 Week High: $39.08 52 Week Low: $10.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.14% -16.94% 12 Week -22.77% -13.21% Year To Date -39.11% -25.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 15440 LAGUNA CANYON ROAD SUITE 160 - IRVINE,CA 92618 USA ph: 949-409-9820 fax: - ir@tarsusrx.com http://www.tarsusrx.com

• General Corporate Information    Officers Bobak Azamian - President; Chief Executive Officer and Director Michael Ackermann - Chairman Leonard M. Greenstein - Chief Financial Officer Bhaskar Chaudhuri - Director Rosemary Crane - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87650L103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/03/22 Share - Related Items Shares Outstanding: 20.73 Most Recent Split Date: (:1) Beta: 1.44 Market Capitalization: $283.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.37 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.90 Price/Cash Flow: - Price / Sales: 11.77 EPS Growth vs. Year Ago Period: -308.51% vs. Previous Quarter: -36.11% Sales Growth vs. Year Ago Period: -98.39% vs. Previous Quarter: 59.47% ROE 03/31/22 - -25.85 12/31/21 - -7.66 09/30/21 - -5.80 ROA 03/31/22 - -23.57 12/31/21 - -7.21 09/30/21 - -5.50 Current Ratio 03/31/22 - 14.18 12/31/21 - 15.33 09/30/21 - 18.05 Quick Ratio 03/31/22 - 14.18 12/31/21 - 15.33 09/30/21 - 18.05 Operating Margin 03/31/22 - -184.14 12/31/21 - -24.25 09/30/21 - - Net Margin 03/31/22 - -184.14 12/31/21 - -24.25 09/30/21 - - Pre-Tax Margin 03/31/22 - -185.21 12/31/21 - -24.15 09/30/21 - -18.42 Book Value 03/31/22 - 7.20 12/31/21 - 8.06 09/30/21 - 8.71 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.13 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 11.39 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©